A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

Trial Profile

A Phase 3, Multinational, Randomized, Placebo-Controlled Study of ARRY-371797 in Patients With Symptomatic Dilated Cardiomyopathy Due to a Lamin A/C Gene Mutation

Recruiting
Phase of Trial: Phase III

Latest Information Update: 16 Sep 2018

At a glance

  • Drugs ARRY 797 (Primary)
  • Indications Dilated cardiomyopathy
  • Focus Registrational; Therapeutic Use
  • Sponsors Array BioPharma
  • Most Recent Events

    • 31 Aug 2018 Biomarkers information updated
    • 20 Mar 2018 Status changed from not yet recruiting to recruiting.
    • 06 Feb 2018 According to an Array BioPharma media release, this trial is expected to begin in this quarter.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top